Download Files:
Ponesimod
$110 – $935
Products Details
Product Description
– Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation[1][2][3].
Web ID
– HY-10569
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C23H25ClN2O4S
References
– [1]Piali L, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547-56.|[2]Bolli MH, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010 May 27;53(10):4198-211.|[3]Brossard P, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76(6):888-96.
CAS Number
– 854107-55-4
Molecular Weight
– 460.97
Compound Purity
– 99.81
SMILES
– O=C1N(C2=CC=CC=C2C)/C(S/C1=CC3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC
Clinical Information
– Launched
Research Area
– Inflammation/Immunology
Solubility
– DMSO : ≥ 100 mg/mL
Target
– LPL Receptor
Isoform
– S1PR1;S1PR3;S1PR4;S1PR5
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
